It has been reported that tumor-infiltrating monocytes and NK cells that can be found in breast tumors could show high HER2-trogocytosis, mainly when patients are treated with mAbs systemic treatment, which facilitate NK cell recruitment and activation (47). This evidence concerns the gene ERBB2 and neoplasm.